Legend Biotech Corporation (LEGN)

Legend Biotech is trading near the bottom of its 52-week range after a sharp week: the stock is down 14.19% over one week and sits at $19.54, 16% of the way up a range running from $16.24 to $37.50. Last session it fell 4.26% on volume 55.9% above its average, a move that came as the shares remain below both their 50-day and 200-day averages. The stock is down 38.99% over the past year, though it is up 9.78% over the past month. The question for holders now is whether the recent bounce off the lows can hold while the trend stays negative. Analysts have not followed the price lower: eight of 13 rate the stock Buy, none rate it Sell, and the median 12-month target is $48.00. CleaRank rates the stock Hold, with a score of 56 out of 100, a more cautious reading than Wall Street's Buy consensus.

The trend is negative on every measure CleaRank tracks: the price sits below its 50-day and 200-day moving averages ($19.72 and $22.19), and the 50-day average is itself below the 200-day average. The stock is 0.93% below its 50-day simple moving average and 11.95% below its 200-day average, and the 50-day average itself sits 11.12% below the 200-day average. Those three readings all point the same way, which is why the trend is the factor pulling CleaRank's score down most. The stock is also 7.05% below its 20-day exponential average, so the recent bounce has not yet pushed the short-term average back above the price.

No company event in the available reporting explains these moves, so the decline cannot be tied to a stated cause. What the figures do show is that the selling came with heavier trading than usual, which tends to mark a move that many holders acted on at once.

Eight of 13 analysts rate the stock Buy, five rate it Hold, and none rate it Sell. Eleven of 15 ratings three months earlier were Buy, so the number of Buy ratings has dropped from 11 to 8 over that span. Barclays kept its Overweight rating on October 13, 2026 and on September 11, 2026, and HC Wainwright & Co. kept its Buy rating on September 30 and September 4, 2026. JP Morgan kept its Neutral rating on October 9, 2026, and RBC Capital kept its Outperform rating on October 8, 2026. The median target of $48.00 sits 145.6% above the price, a gap that tells you how far analysts expect the valuation to recover if their forecasts hold.

The company is not yet profitable: the net profit margin is -7.21%, the operating margin is 2.75%, and return on equity is -0.02%, below the sector median of 7.3%. Debt is modest, with a debt-to-equity ratio of 0.13. Revenue grew 51.93% in the latest quarter year on year, against a sector median of 8.1%, so growth is strong but has not yet reached the bottom line.

Our base case is that the stock trades in a range between its recent low of $16.24 and the 50-day average near $19.72 until the trend improves. Revenue growth of 51.93% in the latest quarter, year on year, and analysts' expectation of 39.7% revenue growth this fiscal year are the fundamental support for that case. Analysts' expected loss of $0.01 per share this fiscal year, against $0.68 next year, means the earnings turn has to arrive on schedule. The case weakens if the price breaks below the $16.24 low, which would confirm the downtrend and remove the cushion the stock has held through the past year. Analyst targets range from $24.00 to $68.00, with a median of $48.00, so the gap between price and targets is wide; it will only narrow if the company shows the profit and returns that analysts are modelling. Market moves of about 4.58% a day, measured by the 30-day standard deviation, mean that a single session can erase a large share of a week's gain.

Support sits at $16.24, the 52-week low, which is the nearest level below the price and the one a fall would meet first. Above the price, the first resistance is the 50-day simple moving average at $19.72, which the stock sits just below. The 20-day exponential moving average at $21.02 comes next and marks where short-term momentum would need to recover. The 200-day simple moving average at $22.19 is the longer-term trend line that the stock has been below. The 52-week high of $37.50 is the far ceiling and the level that would require a sustained rally to reach.